Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

29
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
29
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

46
Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
46
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

95
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
95
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.4K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.4K
Antifungal Agents01:15

Antifungal Agents

37
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
37
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

135
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
135

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pyrithione: A Privileged Structure with the Essential Pharmacophore for Inhibiting Zinc Metalloenzymes.

Mini reviews in medicinal chemistry·2026
Same author

An overview of outer membrane protein A (OmpA) as a therapeutic target for <i>Acinetobacter baumannii</i> infection.

Expert opinion on therapeutic targets·2026
Same author

Investigation of Three Flavonoids as Potent Tau Aggregation Inhibitors and <i>In vivo</i> Demonstration of Myricetin.

Pharmacological research. Natural products·2026
Same author

Repurposing the Anticancer Drug KP46 to Beat the CRAB out of Resistance: Towards an Orally Active Ga-Based Antiplantonic and Antibiofilm Agent.

Antibiotics (Basel, Switzerland)·2025
Same author

Comprehensive in silico analysis of Acinetobacter isolates from South Korea reveals genomic diversity, antimicrobial resistance, virulence factors, and evolutionary dynamics.

Genes & genomics·2025
Same author

Harnessing the synergy of copper nanoparticles and vitamin C towards the resolution of wound infection.

Biomaterials science·2025

Related Experiment Video

Updated: Mar 29, 2026

Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance
06:42

Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance

Published on: September 27, 2024

3.1K

Iron(III)-Tropolone Complex as a Topical Agent Against Drug-Resistant MRSA Skin Infections.

Nalin Abeydeera1, Guanyu Chen1, Khalil Zarea2

  • 1Department of Chemistry and Biochemistry, Kent State University, Kent, OH 44240, USA.

Antibiotics (Basel, Switzerland)
|March 27, 2026
PubMed
Summary
This summary is machine-generated.

A novel iron compound, Fe(tropo)3, shows potent activity against drug-resistant Staphylococcus aureus (SA) skin infections. This non-antibiotic topical agent effectively kills bacteria and reduces biofilms, offering a promising alternative for managing resistant SA strains.

Keywords:
Fe-based antimicrobialsFenton reactionbacterial iron metabolismmetal chelationmethicillin-resistant Staphylococcus aureus

More Related Videos

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro
11:52

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro

Published on: April 21, 2023

4.2K
Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress
11:00

Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress

Published on: August 31, 2015

8.8K

Related Experiment Videos

Last Updated: Mar 29, 2026

Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance
06:42

Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance

Published on: September 27, 2024

3.1K
Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro
11:52

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro

Published on: April 21, 2023

4.2K
Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress
11:00

Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress

Published on: August 31, 2015

8.8K

Area of Science:

  • Antimicrobial resistance
  • Topical drug development
  • Iron-based therapeutics

Background:

  • Widespread use of mupirocin and fusidic acid has led to Staphylococcus aureus (SA) resistance.
  • Limited effectiveness of current topical agents against resistant SA strains.

Purpose of the Study:

  • Evaluate Fe(tropo)3, an iron(III)-tropolone complex, as a non-antibiotic topical antimicrobial.
  • Assess its efficacy against drug-resistant SA skin infections.

Main Methods:

  • In vitro testing against various SA strains (MSSA, MRSA, vancomycin-intermediate).
  • Evaluation of Fe(tropo)3's mechanism of action (cell penetration, ROS generation).
  • In vivo testing in a murine wound infection model with a 1% topical ointment formulation.

Main Results:

  • Fe(tropo)3 demonstrated potent activity (MIC 2 µg/mL) against all tested SA isolates.
  • The compound induced bacterial cell death via reactive oxygen species and showed antibiofilm activity.
  • A 1% topical ointment achieved 98% reduction in bacterial load in a murine model without irritation.

Conclusions:

  • Fe(tropo)3 is a promising topical antimicrobial with a distinct mechanism of action.
  • It offers potential utility against resistant SA where standard care is compromised.
  • Further clinical relevance is supported by pilot study findings.